Lung - Cancer

Video

SCTS 2026 | Challenges in the Management of Locally Advanced NSCLC

May 22, 2026 | Enrico Ruffini…

At the Society for Cardiothoracic Surgery in Great Britain and Ireland Annual Meeting, leading surgeons presented on challenges in the management of locally advanced non-small cell lung cancer (NSCLC). Dr. Enrico Ruffin, Professor of Thoracic...

JANS Article

Right Basilar Segmental Autologous Lung Transplantation With Carinal Reconstruction for Central Lung SCC

September 24, 2026 | Akshay PatelSilver Contributor

This case report describes a 75-year-old patient with a centrally located squamous cell carcinoma extending from the carina to the right intermediate bronchus and the superior segment of the lower...

JANS Article

An STS General Thoracic Surgery Database Analysis of the Association Between LN Dissection and Chylothorax

September 24, 2026 | Akshay PatelSilver Contributor

This Society of Thoracic Surgeons General Thoracic Surgery Database analysis found that postoperative chylothorax risk increases with the extent of lymph-node dissection during pulmonary resection. Although uncommon, chylothorax was associated...

Podcast

The Beat With Joel Dunning Ep. 173: Uniportal Robotics in the UAE

September 10, 2026 | Joel DunningGold ContributorSilver Commentor

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Taj Mohammed Fiyaz Chowdhry, a consultant thoracic surgeon at Burjeel Specialty Hospital, Sharjah, UAE, about uniportal robotics in the...

JANS Article

Tumor Mutational Burden as a Predictor of Immune-Related Adverse Events in Patients With Advanced Non-Small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors: A Brief Report

September 3, 2026 | Akshay PatelSilver Contributor

High tumor mutational burden (TMB) predicts not only response to immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) but also immune-related toxicity. In this single-center cohort of...

JANS Article

Persistent N2 After Induction Is Not a Contraindication to Surgery for Lung Cancer

August 19, 2022 | Mary Hammon

Surgical management for potentially resectable stage IIIA-N2 non-small cell lung cancer (NSCLC) is controversial. In this study, researchers examined outcomes of a well-selected surgical cohort of postinduction IIIA-N2 NSCLC patients...

JANS Article

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

May 26, 2022 | Aristotle ProtopapasGold Commentor

No statistical significance ,between the two arms, regarding the OVERALL survival in this RCT funded by the supplier and manufacturer of the immunotherapy in question….

...
JANS Article

Lung Cancer in France

January 27, 2021 | Aristotle ProtopapasGold Commentor

An open-access detailed editorial from the official periodical of the International Association for the Study of Lung Cancer

...
JANS Article

Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-small Cell Lung Cancer

November 21, 2020 | Aristotle ProtopapasGold Commentor

A scholarly and sober narrative review on , as the authors state, a ‘ hot topic’ that is already being debated in Multidisciplinary Meetings and Lung Cnacer Boards.

...
JANS Article

Ethnic Disparities in PET/CT Utilization at Diagnosis of Non-Small Cell Lung Cancer

March 18, 2020 | Mark FergusonBronze Contributor

The authors examined the SEER database to assess racial disparities in use of PET for lung cancer staging 2007-2015 and subsequent one-year survival. Blacks (OR 0.54) and Hispanics (OR 0.72)...

JANS Article

Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline

February 8, 2020 | Mark FergusonBronze Contributor

The newest version of the ASCO guidelines for lung cancer surveillance after curative lung cancer therapy is presented. The overall quality of supportive evidence is low, and the strength of...

JANS Article

Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial

February 1, 2020 | Mark FergusonBronze Contributor

Individuals at high risk for lung cancer were randomized to low dose CT screening (years 0, 1, 3, and 5.5) or observation. At 10 years the cumulative rate ratio for...

JANS Article

A Remarkable Drop in Lung Cancer Mortality

January 10, 2020 | Mark FergusonBronze Contributor

Declines in US annual lung cancer mortality rates of 5% for men and 4% for women led improvements in overall cancer mortality rates in the latest update from the American...

LOAD MORE
ADVERTISE ON CTSNET